APA (7th ed.) Citation

Calabresi, P. A., Radue, E., Goodin, D., Jeffery, D., Rammohan, K. W., Reder, A. T., . . . Lublin, F. D. (2014). Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet neurology, 13(6), 545-556. https://doi.org/10.1016/S1474-4422(14)70049-3

Chicago Style (17th ed.) Citation

Calabresi, Peter A., et al. "Safety and Efficacy of Fingolimod in Patients with Relapsing-remitting Multiple Sclerosis (FREEDOMS II): A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial." Lancet Neurology 13, no. 6 (2014): 545-556. https://doi.org/10.1016/S1474-4422(14)70049-3.

MLA (9th ed.) Citation

Calabresi, Peter A., et al. "Safety and Efficacy of Fingolimod in Patients with Relapsing-remitting Multiple Sclerosis (FREEDOMS II): A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial." Lancet Neurology, vol. 13, no. 6, 2014, pp. 545-556, https://doi.org/10.1016/S1474-4422(14)70049-3.